ReviewVeterinary world2025
Benefits of aromatase blockers for increased testosterone in poultry: A mini-review.
Review in Veterinary world, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Testosterone is a key androgenic hormone in male poultry, regulating growth performance, reproductive function, and the development of secondary sexual characteristics. However, endogenous testosterone levels are often diminished through conversion to estrogen through the aromatase enzyme, presenting a physiological constraint in poultry production systems. While synthetic testosterone administration has been employed to overcome this limitation, it is frequently accompanied by adverse effects, including gonadal atrophy and impaired spermatogenesis. Consequently, aromatase blockers have emerged as a promising strategy to enhance testosterone levels by inhibiting estrogen biosynthesis. This review synthesizes current evidence on both synthetic aromatase blockers (SABs), such as letrozole and tamoxifen, and natural aromatase blockers (NAB), including compounds derived from
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.